HNSCC
91
38
47
21
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
4.4%
4 terminated out of 91 trials
84.0%
-2.5% vs benchmark
7%
6 trials in Phase 3/4
38%
8 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (91)
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
High-Resolution PET-CT Imaging for Surgical Margin Visualization